{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:14:42Z","timestamp":1790457282131,"version":"4.1.0"},"reference-count":31,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,11,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Connatal pneumonia caused by group B streptococcal (GBS) infection may be associated with surfactant dysfunction. We investigated the effects of surfactant treatment in term and preterm neonates with GBS infection and respiratory failure, in comparison with corresponding data from a control population of noninfected infants treated with surfactant for respiratory distress syndrome (RDS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design\/Methods.<\/jats:title><jats:p>The study comprised 118 infants with respiratory failure, clinical and\/or laboratory signs of acute inflammatory disease, and GBS infection proven by culture results. They were recruited retrospectively from a database of patients treated with surfactant at 28 neonatology units participating in European multicenter trials (1987\u20131993) and prospectively from the same units in the following years. A nonrandomized control group of 236 noninfected infants was selected from the same database. The primary parameters evaluated were oxygen requirement, ventilator settings, and incidence of complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Median birth weight in the GBS study group was 1468 g (25th\u201375th percentiles: 1015\u20132170), and median gestational age was 30 (27\u201333) weeks. Thirty-one percent of the infants weighed &amp;gt;2000 g. Median age at surfactant treatment was 6 hours. The mean initial surfactant dose was 142 mg\/kg (standard deviation: 53). Ninety of the infants were treated with Curosurf (Chiesi Farmaceutici, Parma, Italy), 13 with Survanta (Abboth GmbH, Wiesbaden, Germany), 12 with Alveofact (Dr Karl Thomae GmbH, Biberach, Germany), and 3 with Exosurf (Wellcome GmbH, Burgwedel, Germany). Within 1 hour of surfactant treatment, median fraction of inspiratory oxygen was reduced from .84 (25th\u201375th percentiles: .63\u20131.0) to .50 (.35\u2013.80). The incidence of complications in the study group (mortality: 30%; pneumothorax: 16%; intracranial hemorrhage: 42%) was high, compared with infants with RDS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions.<\/jats:title><jats:p>Surfactant therapy improves gas exchange in the majority of patients with GBS pneumonia. The response to surfactant is slower than in infants with RDS, and repeated surfactant doses are often needed. The mortality and morbidity are substantial, considering the relatively high mean birth weight of the treated infants.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.106.5.957","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:50:41Z","timestamp":1092441041000},"page":"957-964","source":"Crossref","is-referenced-by-count":101,"title":["Surfactant Treatment of Neonates With Respiratory Failure and Group B Streptococcal Infection"],"prefix":"10.1542","volume":"106","author":[{"given":"Egbert","family":"Herting","sequence":"first","affiliation":[{"name":"From the Departments of Pediatrics, University of Go\u0308ttingen, Go\u0308ttingen, Germany;"},{"name":"Division for Experimental Perinatal Pathology, Department of Woman and Child Health, Karolinska Institute, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Gefeller","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen-Nuremberg, Nuremberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Land","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen-Nuremberg, Nuremberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loekie","family":"van Sonderen","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands; and the"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Harms","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics, University of Go\u0308ttingen, Go\u0308ttingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Robertson","sequence":"additional","affiliation":[{"name":"Division for Experimental Perinatal Pathology, Department of Woman and Child Health, Karolinska Institute, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Members of the Collaborative European Multicenter Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2000,11,1]]},"reference":[{"key":"2021121003313710100_B1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0022-3476(05)81801-3","article-title":"Early onset group B-streptococcal sepsis: a current assessment.","volume":"121","author":"Weisman","year":"1992","journal-title":"J Pediatr"},{"key":"2021121003313710100_B2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJM197601082940201","article-title":"A comparison of early onset group B streptococcal neonatal infection and the respiratory distress syndrome.","volume":"294","author":"Ablow","year":"1976","journal-title":"N Eng J Med"},{"key":"2021121003313710100_B3","doi-asserted-by":"crossref","first-page":"F3","DOI":"10.1136\/fn.76.1.F3","article-title":"Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia.","volume":"76","author":"Herting","year":"1997","journal-title":"Arch Dis Child"},{"key":"2021121003313710100_B4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1542\/peds.87.1.101","article-title":"Surfactant treatment of full-term newborns with respiratory failure.","volume":"87","author":"Auten","year":"1991","journal-title":"Pediatrics"},{"key":"2021121003313710100_B5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1542\/peds.92.1.135","article-title":"Surfactant therapy in full-term neonates with severe respiratory failure.","volume":"92","author":"Khammash","year":"1993","journal-title":"Pediatrics"},{"key":"2021121003313710100_B6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-3476(98)70482-2","article-title":"Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure: Survanta in term infants study group.","volume":"132","author":"Lotze","year":"1998","journal-title":"J Pediatr"},{"key":"2021121003313710100_B7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1542\/peds.82.5.683","article-title":"Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial.","volume":"82","author":"Collaborative European Multicenter Study Group","year":"1988","journal-title":"Pediatrics"},{"key":"2021121003313710100_B8","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/BF02718222","article-title":"Early and late surfactant replacement therapy in severe respiratory distress syndrome.","volume":"148","author":"Speer","year":"1990","journal-title":"Lung"},{"key":"2021121003313710100_B9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1542\/peds.89.1.13","article-title":"Randomised European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf.","volume":"89","author":"Speer","year":"1992","journal-title":"Pediatrics"},{"key":"2021121003313710100_B10","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1136\/fn.72.1.F8","article-title":"Randomized clinical trial of surfactant therapy for neonatal respiratory distress syndrome: comparison of two treatment regimens with natural surfactant preparations.","volume":"72","author":"Speer","year":"1995","journal-title":"Arch Dis Child"},{"key":"2021121003313710100_B11","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1159\/000243840","article-title":"Factors influencing morbidity and mortality in infants with severe respiratory distress syndrome treated with single or multiple doses of a natural porcine surfactant.","volume":"61","author":"Herting","year":"1992","journal-title":"Biol Neonate"},{"key":"2021121003313710100_B12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","article-title":"Reducing bias in observational studies using subclassification on the propensity score.","volume":"79","author":"Rosenbaum","year":"1994","journal-title":"J Am Stat Assoc"},{"key":"2021121003313710100_B13","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomised control group.","volume":"17","author":"D'Agostino","year":"1998","journal-title":"Stat Med"},{"key":"2021121003313710100_B14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00974058","article-title":"Acute pulmonary radiograph changes in hyaline membrane disease treated with artificial ventilation and positive end-exspiratory pressure (PEEP).","volume":"1","author":"Giedion","year":"1973","journal-title":"Pediatr Radiol"},{"key":"2021121003313710100_B15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0095-5108(18)30184-2","article-title":"Group B streptococcal infections.","volume":"24","author":"Baker","year":"1997","journal-title":"Clin Perinatol"},{"key":"2021121003313710100_B16","first-page":"1","article-title":"Prevention of perinatal group B streptococcal disease: a public health perspective.","volume":"45","author":"Schuchat","year":"1996","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021121003313710100_B17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1542\/peds.99.3.489","article-title":"Revised guidelines for prevention of early-onset group B-streptococcal (GBS) infection.","volume":"99","author":"American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn","year":"1997","journal-title":"Pediatrics"},{"key":"2021121003313710100_B18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0002-9378(97)70206-0","article-title":"High expression of tumor necrosis factor-alpha and interleukin-6 in periventricular leukomalacia.","volume":"177","author":"Yoon","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"2021121003313710100_B19","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jama.1997.03550120049032","article-title":"Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes: a randomised controlled trial.","volume":"278","author":"Mercer","year":"1997","journal-title":"JAMA"},{"key":"2021121003313710100_B20","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1001\/jama.1993.03510120064032","article-title":"Comparison of prevention strategies for neonatal group B streptococcal infection: a population based economic analysis.","volume":"270","author":"Mohle-Boetani","year":"1993","journal-title":"JAMA"},{"key":"2021121003313710100_B21","doi-asserted-by":"crossref","first-page":"F170","DOI":"10.1136\/fn.71.3.F170","article-title":"Prognostic value of immediate response to surfactant.","volume":"71","author":"Kuint","year":"1995","journal-title":"Arch Dis Child"},{"key":"2021121003313710100_B22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1542\/peds.97.1.48","article-title":"Surfactant replacement therapy for meconium aspiration syndrome.","volume":"97","author":"Findlay","year":"1996","journal-title":"Pediatrics"},{"key":"2021121003313710100_B23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1164\/ajrccm.154.1.8680699","article-title":"Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis.","volume":"154","author":"Walmrath","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"2021121003313710100_B24"},{"key":"2021121003313710100_B25","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0022-3476(05)82013-X","article-title":"Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits.","volume":"125","author":"Sherman","year":"1994","journal-title":"J Pediatr"},{"key":"2021121003313710100_B26","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1203\/00006450-199412000-00017","article-title":"Experimental neonatal group B streptococcal pneumonia: effect of a modified porcine surfactant on bacterial proliferation in ventilated near-term rabbits.","volume":"36","author":"Herting","year":"1994","journal-title":"Pediatr Res"},{"key":"2021121003313710100_B27","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.4049\/jimmunol.158.9.4336","article-title":"Surfactant protein A-deficient mice are susceptible to group B streptococcal infection.","volume":"158","author":"LeVine","year":"1997","journal-title":"J Immunol"},{"key":"2021121003313710100_B28"},{"key":"2021121003313710100_B29","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1164\/ajrccm\/144.4.909","article-title":"Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs.","volume":"144","author":"Kharasch","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"2021121003313710100_B30","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1476-5381.1996.tb16016.x","article-title":"Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae.","volume":"119","author":"van't Veen A, Mouton JW, Gommers D, Lachmann B","year":"1996","journal-title":"Br J Pharmacol"},{"key":"2021121003313710100_B31","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1164\/ajrccm.159.6.9810047","article-title":"Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B-streptococcal pneumonia.","volume":"159","author":"Herting","year":"1999","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/106\/5\/957\/841906\/957.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/106\/5\/957\/841906\/957.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:31:32Z","timestamp":1682746292000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/106\/5\/957\/63206\/Surfactant-Treatment-of-Neonates-With-Respiratory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11,1]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2000,11,1]]},"published-print":{"date-parts":[[2000,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.106.5.957","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[2000,11,1]]}}}